Modern science offers a novel strategy to target the most challenging infections fueled by biofilms. Learn more about our important work to combat these infections and reduce antibiotic resistance.Our Science An innovative, strategically focused management team with deep anti-infective therapeutic and vaccine development expertise.Meet The Team In the News Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody TherapyJune 1, 2023 Clarametyx Biosciences Announces Changes to Its Scientific Advisory BoardMay 30, 2023 Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial PneumoniaNovember 30, 2022 Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101October 5, 2022